PMID- 23683537
OWN - NLM
STAT- MEDLINE
DCOM- 20140501
LR  - 20190221
IS  - 1872-8332 (Electronic)
IS  - 0169-5002 (Linking)
VI  - 81
IP  - 2
DP  - 2013 Aug
TI  - Coexistence of EGFR mutation and ALK translocation in NSCLC: literature review 
      and case report of response to gefitinib.
PG  - 294-6
LID - S0169-5002(13)00159-1 [pii]
LID - 10.1016/j.lungcan.2013.04.009 [doi]
AB  - The coexistence of EGFR and ALK-EML4 gene mutations represents a rare event 
      (about 1%) in patients with non small cell lung cancer (NSCLC) and the few cases 
      described in the literature have all been treated by different methods. We 
      present the case of a 52-year-old woman with adenocarcinoma of the lung whose 
      tumor had this double genetic aberration. The patient was immediately treated 
      with gefitinib because the tumor was judged inoperable, but after two months she 
      obtained an important clinical remission and was submitted to radical surgery. 
      She is currently undergoing adjuvant treatment with gefitinib. A review of the 
      literature on this double genetic aberration highlighted that further research is 
      needed to define the best therapeutic approach.
CI  - Copyright (c) 2013 Elsevier Ireland Ltd. All rights reserved.
FAU - Santelmo, C
AU  - Santelmo C
AD  - U.O. Oncologia, Ospedale Infermi Rimini, 2 Settembrini Street, Rimini, Italy. 
      carlotta.santelmo@alice.it
FAU - Ravaioli, A
AU  - Ravaioli A
FAU - Barzotti, E
AU  - Barzotti E
FAU - Papi, M
AU  - Papi M
FAU - Poggi, B
AU  - Poggi B
FAU - Drudi, F
AU  - Drudi F
FAU - Mangianti, M
AU  - Mangianti M
FAU - Salvi, M
AU  - Salvi M
FAU - Crino, L
AU  - Crino L
LA  - eng
PT  - Case Reports
PT  - Journal Article
DEP - 20130514
PL  - Ireland
TA  - Lung Cancer
JT  - Lung cancer (Amsterdam, Netherlands)
JID - 8800805
RN  - 0 (Cell Cycle Proteins)
RN  - 0 (Microtubule-Associated Proteins)
RN  - 0 (Quinazolines)
RN  - EC 2.7.10.1 (ALK protein, human)
RN  - EC 2.7.10.1 (Anaplastic Lymphoma Kinase)
RN  - EC 2.7.10.1 (EGFR protein, human)
RN  - EC 2.7.10.1 (ErbB Receptors)
RN  - EC 2.7.10.1 (Receptor Protein-Tyrosine Kinases)
RN  - EC 3.4.21.- (EML4 protein, human)
RN  - EC 3.4.21.- (Serine Endopeptidases)
RN  - S65743JHBS (Gefitinib)
SB  - IM
MH  - Adenocarcinoma/drug therapy/enzymology/genetics/metabolism
MH  - Adenocarcinoma of Lung
MH  - Anaplastic Lymphoma Kinase
MH  - Carcinoma, Non-Small-Cell Lung/*drug therapy/enzymology/genetics/metabolism
MH  - Cell Cycle Proteins/genetics
MH  - ErbB Receptors/*genetics
MH  - Female
MH  - Gefitinib
MH  - Humans
MH  - Lung Neoplasms/*drug therapy/enzymology/genetics/metabolism
MH  - Microtubule-Associated Proteins/genetics
MH  - Middle Aged
MH  - *Mutation
MH  - Quinazolines/*therapeutic use
MH  - Receptor Protein-Tyrosine Kinases/*genetics
MH  - Serine Endopeptidases/genetics
OTO - NOTNLM
OT  - ALK translocation
OT  - Double mutation
OT  - EGFR mutation
OT  - Gefitinib
OT  - Neoadjuvant chemotherapy
OT  - Non small cell lung cancer
EDAT- 2013/05/21 06:00
MHDA- 2014/05/03 06:00
CRDT- 2013/05/21 06:00
PHST- 2012/11/01 00:00 [received]
PHST- 2013/04/06 00:00 [revised]
PHST- 2013/04/08 00:00 [accepted]
PHST- 2013/05/21 06:00 [entrez]
PHST- 2013/05/21 06:00 [pubmed]
PHST- 2014/05/03 06:00 [medline]
AID - S0169-5002(13)00159-1 [pii]
AID - 10.1016/j.lungcan.2013.04.009 [doi]
PST - ppublish
SO  - Lung Cancer. 2013 Aug;81(2):294-6. doi: 10.1016/j.lungcan.2013.04.009. Epub 2013 
      May 14.